BP44315

A trial evaluating the safety and pharmacokinetics/pharmacodynamics of a bispecific antibody (CD19/CD3) in systemic lupus erythematosus. A multicentre phase 1 trial

Condition studied : Systemic lupus erythematosus
Treatment : Administration of a bispecific CD19/CD3 antibody
Sponsor : Roche
Principal Investigator : Dr. Alexandre Maria
: NCT 05835986, EU Trial 2022-502632-39-00
Investigator
Dr. Alexandre Maria
Internal medicine specialist
Rechercher sur le site